The Life Sciences team advised Sofinnova Partners, Intermediate Capital Group as lead investors as well as new investors Tekla and CTI Life Sciences, in Amolyt Pharma €130 Million in Series C Financing. The financing also included the participation of existing investors Andera Partners, Novo Holdings (Novo Ventures), Kurma Partners, EQT Life Sciences, Innobio 2 managed by Bpifrance Investissement, Sectoral Asset Management, Pontifax, Orbimed, Mass General Brigham Ventures, ATEM, Credit Agricole Creation and Sham Innovation Santé/Turenne Capital.
The funds will be used to complete Phase 3 clinical development of eneboparatide (AZP-3601) for hypoparathyroidism, and advance AZP-3813 into the clinic for acromegaly.
Amolyt Pharma is a global company specializing in developing therapeutic peptides for rare endocrine and related diseases.
The Goodwin team was led by Anne-Charlotte Rivière and included Félicien Bardsley, Julie Messerig, Marie Fillon, Louis de Chezelles, Marie-Laure Bruneel, Kristina Bieker, Vicente Nunez, Pavel A. Puzerey, Lily Xu, Stephanie Philbin and Emily Tribulski.
For additional details on the financing, please read the press release.